Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult
subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to
available therapies and for which no standard or available curative therapy exists